{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:50Z","timestamp":1793047070076,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.schres.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T22:33:02Z","timestamp":1779834782000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Omega-3 polyunsaturated fatty acids for the management of metabolic syndrome in psychotic disorders: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"295","author":[{"given":"A.","family":"Rainford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lochtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9491","key":"10.1016\/j.schres.2026.05.004_bb0005","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome--a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.schres.2026.05.004_bb0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/070674371305800705","article-title":"Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial","volume":"58","author":"Amminger","year":"2013","journal-title":"Can. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.schres.2026.05.004_bb0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.psychres.2017.12.028","article-title":"Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate","volume":"261","author":"Behdani","year":"2018","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.schres.2026.05.004_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2013.110","article-title":"A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia","volume":"3","author":"Bentsen","year":"2013","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.05.004_bb0030","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/sj.npp.1301628","article-title":"Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study","volume":"33","author":"Berger","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.schres.2026.05.004_bb0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/j.1440-1614.2006.01869.x","article-title":"Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine","volume":"40","author":"Caniato","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"DEH","year":"2009","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2026.05.004_bb0045","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1176\/appi.ajp.159.9.1596","article-title":"Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia","volume":"159","author":"Emsley","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.05.004_bb0050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2007.06.029","article-title":"Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial","volume":"161","author":"Emsley","year":"2008","journal-title":"Psychiatry Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.05.004_bb0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2014.06.004","article-title":"A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia","volume":"158","author":"Emsley","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2008-2231-20-43","article-title":"Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial","volume":"20","author":"Faghihi","year":"2012","journal-title":"Daru"},{"issue":"12","key":"10.1016\/j.schres.2026.05.004_bb0065","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/appi.ajp.158.12.2071","article-title":"A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia","volume":"158","author":"Fenton","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.05.004_bb0070","article-title":"N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics","volume":"7","author":"Fetter JCB","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"3","key":"10.1016\/j.schres.2026.05.004_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/104012371502700306","article-title":"Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia","volume":"27","author":"Freeman","year":"2015","journal-title":"Ann. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.05.004_bb0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0269881120981392","article-title":"Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.05.004_bb0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1192\/bjp.bp.114.160242","article-title":"Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression","volume":"209","author":"Hallahan","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.05.004_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr. Diab. Rep."},{"issue":"4","key":"10.1016\/j.schres.2026.05.004_bb0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2026.05.004_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002087","article-title":"Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucose-insulin homeostasis: a systematic review and meta-analysis of randomised controlled feeding trials","volume":"13","author":"Imamura","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2026.05.004_bb0105","series-title":"The IDF consensus definition of metabolic syndrome in children and adolescents","author":"International Diabetes Federation","year":"2007"},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb9005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinidng necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.schres.2026.05.004_bb0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess early mortality in schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"7","key":"10.1016\/j.schres.2026.05.004_bb0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ajh\/hpu024","article-title":"Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials","volume":"27","author":"Miller","year":"2014","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13651501.2024.2310847","article-title":"Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder","volume":"28","author":"Mohd Ahmed","year":"2024","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2026.05.004_bb0125","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2026.05.004_bb0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.schres.2021.02.012","article-title":"Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: findings from the OFFER randomized controlled study","volume":"230","author":"Pawelczyk","year":"2021","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3956(01)00048-6","article-title":"A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms","volume":"36","author":"Peet","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2026.05.004_bb0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2018.09.006","article-title":"A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16\u00a0week randomized placebo-controlled trial for participants concurrently treated with risperidone","volume":"204","author":"Robinson","year":"2019","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2026.05.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2024.1804","article-title":"The therapeutic effect of omega-3 polyunsaturated fatty acids on symptom severity of psychosis: a systematic review and meta-analysis","volume":"67","author":"Rossier","year":"2024","journal-title":"Eur. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.05.004_bb0150","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2026.05.004_bb0155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2020.11.050","article-title":"Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: a randomized clinical trial","volume":"228","author":"Szeszko","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.05.004_bb0160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbi.2020.04.034","article-title":"Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome","volume":"88","author":"Tang","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2026.05.004_bb0165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1192\/bjp.186.6.455","article-title":"Metabolic syndrome and schizophrenia","volume":"186","author":"Thakore","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.05.004_bb0170","series-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2013"},{"issue":"4","key":"10.1016\/j.schres.2026.05.004_bb0175","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00213-018-5136-9","article-title":"Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial","volume":"236","author":"Xu","year":"2019","journal-title":"Psychopharmacology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:05:41Z","timestamp":1793045141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426001489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S0920996426001489"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.05.004","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omega-3 polyunsaturated fatty acids for the management of metabolic syndrome in psychotic disorders: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}